LRP-661, a novel small molecule, demonstrates significant protection across a range of acute and chronic seizure models, positioning it as a promising therapeutic alternative for patients with drug-resistant epilepsy.
The data presented at the ILAE's 15th European Epilepsy Congress in Rome demonstrated that LRP-661, a novel small molecule, exhibits potent anti-seizure activity across various animal models, along with an excellent safety profile.
The findings position LRP-661 as a promising therapeutic alternative for patients suffering from drug-resistant epilepsy.
the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
The advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
Contact Us
Western University Discovery Park, Stiller Centre 700 Collip Circle, Unit 213 London ON Canada N6G 4C4
